Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

BACKGROUND: Immune checkpoint therapy (ICT) prolongs survival in subsets of patients with cancer but can also trigger immune-related adverse events (irAEs) requiring treatment discontinuation. Recent studies have investigated safety of ICT rechallenge after irAEs, and evidence suggests that rechalle...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Immunother Cancer
Hoofdauteurs: Siddiqui, Bilal A, Gheeya, Jinesh S, Goswamy, Rohit, Bathala, Tharakeswara K, Surasi, Devaki Shilpa, Gao, Jianjun, Shah, Amishi, Campbell, Matthew T, Msaouel, Pavlos, Goswami, Sangeeta, Wang, Jennifer, Zurita, Amado J, Jonasch, Eric, Corn, Paul G, Aparicio, Ana M, Siefker-Radtke, Arlene O, Sharma, Padmanee, Subudhi, Sumit K, Tannir, Nizar
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BMJ Publishing Group 2021
Onderwerpen:
Clinical/Translational Cancer Immunotherapy
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8323401/
https://ncbi.nlm.nih.gov/pubmed/34326169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002850
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items